Mohammad Shoukfeh
Cardiovascular Disease · Lubbock, TXNPI 1962405209
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.9% of the total across 132 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Boston Scientific at 24.8% of the total. Reporting peaked in 2019 at $1,805 and has fallen 98.8% since, to $22 in 2023. That places this record below the midpoint for cardiovascular disease clinicians in TX, where the typical reported total is $3,258.
Across 132 payments — averaging $19.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$642
- Amgen$309
- Novartis$289
- AstraZeneca$262
- Johnson & Johnson$235
- Amarin Pharma, Inc.$197
- plus $659 from 11 others
Across 4 payments — averaging $5325.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Esperion Therapeutics, Inc.$14K
- Novartis$6K
- E.r. Squibb & Sons, L.L.C.$2K
What the payments were for
- Food & beverage$2,46095%
- Education$1335%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 21 | $642 |
| Amgen | 17 | $309 |
| Novartis | 16 | $289 |
| AstraZeneca | 12 | $262 |
| Johnson & Johnson | 13 | $235 |
| Amarin Pharma, Inc. | 14 | $197 |
| Boehringer Ingelheim | 8 | $165 |
| Regeneron Healthcare Solutions, Inc. | 10 | $159 |
| E.r. Squibb & Sons, L.L.C. | 5 | $75 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $55 |
| Sanofi-aventis U.S. LLC | 3 | $47 |
| Medtronic | 3 | $42 |
| AbbVie(2 entities) | 2 | $35 |
| Arbor Pharmaceuticals, Inc. | 2 | $32 |
| Gilead | 1 | $18 |
| Pfizer | 1 | $16 |
| Braemar Manufacturing, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYNERGY$209
- GUIDEZILLA$102
How this compares
$2,593 in reported general payments places this provider in the 40th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Lubbock
- Ramin Farzaneh-FarDallas$17.1M
- John OsborneGrapevine$1.3M
- Darren McGuireDallas$1.2M
- Peter McCulloughDallas$664K
- Ann NavarDallas$616K
- Biykem BozkurtHouston$606K
- Milton PackerDallas$530K
- Amarinder BindraDallas$512K
- Robert SalazarKingwood$478K
- Reynolds DelgadoHouston$471K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.